Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $8.86

Shares of Vor Biopharma Inc. (NYSE:VOR) have been given an average recommendation of “Buy” by the seven analysts that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $8.86.

VOR has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright dropped their price objective on Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a report on Friday, March 21st. Oppenheimer reissued an “outperform” rating and set a $8.00 target price on shares of Vor Biopharma in a research note on Friday, March 21st. Stifel Nicolaus dropped their price target on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Wedbush reissued an “outperform” rating and set a $7.00 price objective on shares of Vor Biopharma in a research report on Thursday, March 20th.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock opened at $0.75 on Thursday. The stock has a market capitalization of $51.70 million, a price-to-earnings ratio of -0.46 and a beta of -0.40. The company’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.01. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $2.43.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently modified their holdings of VOR. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Vor Biopharma during the fourth quarter worth about $33,000. Virtu Financial LLC purchased a new position in shares of Vor Biopharma during the fourth quarter valued at approximately $60,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the 4th quarter worth approximately $80,000. Trustees of Columbia University in the City of New York purchased a new stake in shares of Vor Biopharma in the 4th quarter worth approximately $102,000. Finally, Northern Trust Corp increased its position in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after buying an additional 44,252 shares in the last quarter. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.